Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study
- 21 September 2018
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 93 (11) , 1411-1419
Abstract
In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi‐center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event—acute splenic sequestration (ASS), vaso‐occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death—was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow‐up was 19.4 months.During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ‐globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11‐0.73) and 0.16 (0.06‐0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.Keywords
Funding Information
- “Investissements d'avenir” of the French National Research Agency (ANR-11-IDEX-0005-02)
- Laboratory of Excellence GR-Ex (ANR-11-LABX-0051)
- Département de la Recherche Clinique et du Développement de l'Assistance Publique-Hôpitaux de Paris
- French Ministry of Health (P071228)
This publication has 30 references indexed in Scilit:
- Increased Reticulocytosis during Infancy Is Associated with Increased Hospitalizations in Sickle Cell Anemia Patients during the First Three Years of LifePLOS ONE, 2013
- Biomarkers in sickle cell diseaseBritish Journal of Haematology, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemiaBlood, 2011
- Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn CohortBlood, 2008
- Automated analysis of mature red blood cells and reticulocytes in SS and SC diseaseBlood Cells, Molecules, and Diseases, 2004
- Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP studyBlood, 2004
- Prediction of Adverse Outcomes in Children with Sickle Cell DiseaseNew England Journal of Medicine, 2000
- Reference Values and Hematologic Changes From Birth to 5 Years in Patients With Sickle Cell DiseaseArchives of Pediatrics & Adolescent Medicine, 1994
- Rapid analysis of ‐α3.7 thalassaemia and αααanti 3.7 triplication by enzymatic amplification analysisBritish Journal of Haematology, 1993